Year: 2010
Type: article
Abstract: lower than that for both of these agents added sequentially.Interestingly, when the sequence of addition of drugs was reversed using 5azaD/SAHA, the reduction in growth (66% vs. 85%, P , 0.05) and percentage of apoptotic cells were lower than in cultures treated with SAHA/5azaD.The greatest amount of glioma cell death induced by SAHA/5azaD corresponded with higher protein levels of the cyclin dependent kinase inhibitor, P 21 , and the minimum fraction of cells in active phases of cell cycle (19% in control vs. 11% in SAHA/5azaD).Furthermore, glioma cells treated with SAHA/ 5azaD or 5azaD/SAHA displayed the highest levels of acetylated histone H4 protein levels, indicating possible epigenetic changes.Our data indicating that the effects of SAHA/5azaD are likely mediated by epigenetic mechanisms is made evident by increases in P 21 and acetylated histone H4 protein levels.Whether such strategies are also effective in primary human glioma tumor cells will be tested, which may ultimately open untapped territories to search for curative therapies.
Source: Neuro-Oncology
Authors: M. R. Lucas, T. S. Armstrong, A. Acquaye, D. Balachandran, A. Mahajan, D.-H. Kang, E. Vera-Bolanos, M. R. Gilbert, M. P. Lovely, M. Page, K. Mogensen, J. Arzbaecher, C. Amidei, K. Lupica, M. E. Maher, P. Sherwood, S. Kagan, E. M. Sizoo, H. R. W. Pasman, J. C. Reijneveld, J. J. Heimans, L. Deliens, M. J. Taphoorn, R. Sheth, B. T. Bagan, M. N. Baig, C. Karas, D. I. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, J. P. Chandler, K. Muro, M. Marymount, I. B. Helenowski, L. I. Wagner, C. L. Bennett, J. J. Raizer, A. Evans, G. Dhall, J. Finlay, K. Wong, G. McComb, R. Soffietti, R. P. Mueller, U. Abacioglu, S. Villa, F. Fauchon, B. Baumert, L. Fariselli, G. Tridello, M. Kocher, A. Bottomley, C. Pendleton, H. Adams, G. I. Jallo, B. S. Carson, E. Ahn, A. Quinones-Hinojosa, A. A. Acquaye, E. Vera-Bolanos, T. S. Armstrong, B. N. Bekele, M. R. Gilbert, D. I. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, J. Chandler, K. Muro, M. Marymount, I. B. Helenowski, L. I. Wagner, J. J. Raizer, V. Nestor, K. Fink, M. Nashed, M. Linskey, D. A. Bota, W. Hoeben, K. Hilverda, J. J. Heimans, M. J. Taphoorn, T. J. Postma, J. Buter, J. Lenting, E. H. Collette, J. C. Reijneveld, M. Klein, D. van Nieuwenhuizen, L. Bosscher, E. Szymanska, J. J. Heimans, S. M. Peerdeman, M. Klein, J. C. Reijneveld, D. van Nieuwenhuizen, T. Erdmann, J. J. Heimans, J. C. Reijneveld, S. M. Peerdeman, M. Klein, S. N. Lawrence Recht, T. Armstrong, E. Vera-Bolanos, I. Gning, A. Acquaye, M. R. Gilbert, C. Cleeland, T. R. Mendoza, N. Jouniaux-Delbez, J. Y. Delattre, S. T. du Montcel, N. Butowski, R. Parvataneni, A. Nicole, K. Lamborn, M. Polley, J. Clarke, S. Chang, M. Page, M. Prados, A. Liepa, P. Shi, D. Thornton, C. A. Kahlenberg, C. E. Fadul, R. Scott, D. W. Roberts, V. Thadani, K. Bujarski, E. C. Lallana, B. C. Jobst, J. G. Walker, D. Schultz, K. Grisdale, M. D. Groves, K. B. Peters, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, H. S. Friedman, D. H. Allen, B. Carlson, V. Neelon, K. Giovanello, J. Carlson, R. Raynor, A. Desjardins, L. Rice, R. Lall, S. Ha, M. Marymont, S. Grimm, J. Raizer, J. Chandler, K. Muro, S. T. Keir
Language: English
Topic: Cancer survivorship and care
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1524899337